209 related articles for article (PubMed ID: 21737753)
1. Chronic AMP-kinase activation with AICAR reduces adiposity by remodeling adipocyte metabolism and increasing leptin sensitivity.
Gaidhu MP; Frontini A; Hung S; Pistor K; Cinti S; Ceddia RB
J Lipid Res; 2011 Sep; 52(9):1702-11. PubMed ID: 21737753
[TBL] [Abstract][Full Text] [Related]
2. Loss of the anorexic response to systemic 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside administration despite reducing hypothalamic AMP-activated protein kinase phosphorylation in insulin-deficient rats.
Vitzel KF; Bikopoulos G; Hung S; Curi R; Ceddia RB
PLoS One; 2013; 8(8):e71944. PubMed ID: 23967267
[TBL] [Abstract][Full Text] [Related]
3. Chronic AICAR-induced AMP-kinase activation regulates adipocyte lipolysis in a time-dependent and fat depot-specific manner in rats.
Gaidhu MP; Bikopoulos G; Ceddia RB
Am J Physiol Cell Physiol; 2012 Dec; 303(11):C1192-7. PubMed ID: 23054058
[TBL] [Abstract][Full Text] [Related]
4. Regulation of visceral and subcutaneous adipocyte lipolysis by acute AICAR-induced AMPK activation.
Anthony NM; Gaidhu MP; Ceddia RB
Obesity (Silver Spring); 2009 Jul; 17(7):1312-7. PubMed ID: 19214174
[TBL] [Abstract][Full Text] [Related]
5. Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL.
Gaidhu MP; Fediuc S; Anthony NM; So M; Mirpourian M; Perry RL; Ceddia RB
J Lipid Res; 2009 Apr; 50(4):704-15. PubMed ID: 19050316
[TBL] [Abstract][Full Text] [Related]
6. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans.
Steinberg GR; McAinch AJ; Chen MB; O'Brien PE; Dixon JB; Cameron-Smith D; Kemp BE
J Clin Endocrinol Metab; 2006 Sep; 91(9):3592-7. PubMed ID: 16822822
[TBL] [Abstract][Full Text] [Related]
7. 5-Aminoimidazole-4-carboxamide ribonucleotide prevents fat gain following the cessation of voluntary physical activity.
Ruegsegger GN; Sevage JA; Childs TE; Grigsby KB; Booth FW
Exp Physiol; 2017 Nov; 102(11):1474-1485. PubMed ID: 28786140
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with the AMP-kinase activator AICAR increases glycogen storage and fatty acid oxidation in skeletal muscles but does not reduce hyperglucagonemia and hyperglycemia in insulin deficient rats.
Vitzel KF; Bikopoulos G; Hung S; Pistor KE; Patterson JD; Curi R; Ceddia RB
PLoS One; 2013; 8(4):e62190. PubMed ID: 23620811
[TBL] [Abstract][Full Text] [Related]
9. AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle.
Smith AC; Bruce CR; Dyck DJ
J Physiol; 2005 Jun; 565(Pt 2):547-53. PubMed ID: 15774529
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes.
Gaidhu MP; Fediuc S; Ceddia RB
J Biol Chem; 2006 Sep; 281(36):25956-64. PubMed ID: 16816404
[TBL] [Abstract][Full Text] [Related]
11. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition.
Yu X; McCorkle S; Wang M; Lee Y; Li J; Saha AK; Unger RH; Ruderman NB
Diabetologia; 2004 Nov; 47(11):2012-21. PubMed ID: 15578153
[TBL] [Abstract][Full Text] [Related]
12. AMP kinase activation with AICAR simultaneously increases fatty acid and glucose oxidation in resting rat soleus muscle.
Smith AC; Bruce CR; Dyck DJ
J Physiol; 2005 Jun; 565(Pt 2):537-46. PubMed ID: 15774530
[TBL] [Abstract][Full Text] [Related]
13. Dorsal hindbrain 5'-adenosine monophosphate-activated protein kinase as an intracellular mediator of energy balance.
Hayes MR; Skibicka KP; Bence KK; Grill HJ
Endocrinology; 2009 May; 150(5):2175-82. PubMed ID: 19116341
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo.
Hasenour CM; Ridley DE; Hughey CC; James FD; Donahue EP; Shearer J; Viollet B; Foretz M; Wasserman DH
J Biol Chem; 2014 Feb; 289(9):5950-9. PubMed ID: 24403081
[TBL] [Abstract][Full Text] [Related]
15. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats.
Iglesias MA; Ye JM; Frangioudakis G; Saha AK; Tomas E; Ruderman NB; Cooney GJ; Kraegen EW
Diabetes; 2002 Oct; 51(10):2886-94. PubMed ID: 12351423
[TBL] [Abstract][Full Text] [Related]
16. Disruption of AMPKalpha1 signaling prevents AICAR-induced inhibition of AS160/TBC1D4 phosphorylation and glucose uptake in primary rat adipocytes.
Gaidhu MP; Perry RL; Noor F; Ceddia RB
Mol Endocrinol; 2010 Jul; 24(7):1434-40. PubMed ID: 20501641
[TBL] [Abstract][Full Text] [Related]
17. Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle.
Suwa M; Nakano H; Radak Z; Kumagai S
Metabolism; 2011 Mar; 60(3):394-403. PubMed ID: 20362304
[TBL] [Abstract][Full Text] [Related]
18. The effect of AMP-activated kinase activation on gonadotrophin-releasing hormone secretion in GT1-7 cells and its potential role in hypothalamic regulation of the oestrous cyclicity in rats.
Coyral-Castel S; Tosca L; Ferreira G; Jeanpierre E; Rame C; Lomet D; Caraty A; Monget P; Chabrolle C; Dupont J
J Neuroendocrinol; 2008 Mar; 20(3):335-46. PubMed ID: 18194429
[TBL] [Abstract][Full Text] [Related]
19. AMPK activation by A-769662 and 991 does not affect catecholamine-induced lipolysis in human adipocytes.
Kopietz F; Berggreen C; Larsson S; Säll J; Ekelund M; Sakamoto K; Degerman E; Holm C; Göransson O
Am J Physiol Endocrinol Metab; 2018 Nov; 315(5):E1075-E1085. PubMed ID: 30253109
[TBL] [Abstract][Full Text] [Related]
20. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.
Bergeron R; Previs SF; Cline GW; Perret P; Russell RR; Young LH; Shulman GI
Diabetes; 2001 May; 50(5):1076-82. PubMed ID: 11334411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
